Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications
Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.
Journal: The Lancet. Haematology
Published: April 28, 2026
Consolidation Therapy with Checkpoint Inhibitors After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma.
Journal: Transplantation and cellular therapy
Published: March 11, 2026
The clinical applications of next-generation sequencing and ctDNA/cfDNA in lymphoma.
Journal: Clinical advances in hematology & oncology : H&O
Published: February 20, 2026
Short-term costs associated with outpatient use of axicabtagene ciloleucel in second-line and above relapsed/refractory large B-cell lymphoma based on the zuma-24 clinical trial.
Journal: Leukemia & lymphoma
Published: December 08, 2025
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 16, 2025
Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma.
Journal: Blood
Published: September 03, 2025
Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma.
Journal: Blood
Published: September 03, 2025
Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.
Journal: American journal of cancer research
Published: May 19, 2025
Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.
Journal: British journal of haematology
Published: March 20, 2025
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 05, 2025
Last Updated: 09/26/2026